

# Expansion of Biologics CDMO & Manufacturing Capacity Offerings at Paras Biopharmaceuticals Finland Oy

*Pleased to announce that from Q3-2022, company will be in a position to offer an expanded biologics CDMO capacity to European, USA & Canadian groups.*

OULU, FINLAND, March 29, 2022 /EINPresswire.com/ -- Increased capacity offering comes in the form of expanded production timeslots becoming available due to a successful earlier-than-expected conclusion of a previous biologics and biosimilar product development. Due to the company's technologies, its deep scientific knowhow and the specialized skills of the [Paras](#) Biopharma team, all of Paras Biopharmaceutical's project milestones were completed ahead of time.

Paras Biopharma scale-up batches capacities and offerings will be multiple batches/clients at 20L / 150L / 750L scale.



"With the Paras Biopharma teams' continuous strive to work on innovative and challenging projects from clients in the USA and Europe, the main focus on the team is quality and full commitment", says Dr Mark Jackson: Administration Lead.

"Increased capacity offerings will allow Paras Biopharma to undertake new client projects and to deliver them successfully. This will further add to our satisfaction that the company is able to contribute to the field of biologics development and innovation with our biologics manufacturing & [CDMO](#) services", adds Dr Ashesh Kumar, CEO.

Should any company or Development Production group have a need for manufacturing productions slots in Q3 2022 onwards, they are encouraged to reach out to Paras Biopharmaceuticals at [mark.jackson@parasbiopharma.com](mailto:mark.jackson@parasbiopharma.com) to discuss their requirements further.

About Paras Biopharmaceuticals Finland Oy: Paras Biopharmaceuticals Finland Oy has established its expertise in the three critical areas of development and licensing of biosimilar production technologies, enabling the development of complex proteins from early-stage to large scale, and the development and supply of bioprocess enzymes used routinely in biologics development and production.

Paras Biopharmaceuticals has a fully equipped biologics production facility in Finland for the production of recombinant therapeutic products in microbial systems. The state-of-art biologics production plant includes a total floor area of 25,000 ft<sup>2</sup> and a classified cleanroom of 4,300 ft<sup>2</sup>. Other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying. Paras Biopharmaceuticals has a strong pipeline of Biologics & [Biosimilars](#) in Osteoporosis, Rheumatoid Arthritis, Oncology and Metabolic Diseases.

For more information, please see the company pipeline:  
<http://www.parasbiopharma.com/biosimilars/biosimilars.php>

Mark Jackson  
Paras Biopharmaceuticals Finland Oy  
+358 44 2905993  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/566846329>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.